Heart failure affects about 6.2 million people in the United States, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and, like other disease areas, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes.
The HFpEF Drug Discovery & Development Summit is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures.
With 20+ hours of content, an interactive workshop, and over 5 hours of networking with key industry leaders from Amgen, Cardiobiopharma, AstraZeneca, NeoProgen, Eli Lilly, Bayer, Novartis and more, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field.
Network with 80+ senior CSOs, CEOs, research scientists, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide.